{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T01:09:05Z","timestamp":1795223345081,"version":"4.10.3"},"reference-count":25,"publisher":"Georg Thieme Verlag KG","issue":"05","funder":[{"name":"Finnish Cancer Foundation"},{"name":"State Funding for University-level Health Research","award":["TYH2020206"],"award-info":[{"award-number":["TYH2020206"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endoscopy"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Primary sclerosing cholangitis (PSC) is associated with a high risk of hepatobiliary\n        malignancy, especially cholangiocarcinoma (CCA). There are no good tumor markers to screen\n        for CCA, and current recommendations for PSC monitoring are mainly based on expert opinions.\n        The optimal strategy to assess disease progression and screen for CCA \u2013 the main cause of\n        death of PSC patients \u2013 remains unclear. We aimed to compare three different surveillance\n        strategies and their effect on patient outcomes.<\/jats:p>\n                  <jats:p>Data from three distinct PSC cohorts with different surveillance strategies \u2013 scheduled endoscopic retrograde cholangiopancreatography (ERCP), annual magnetic resonance imaging\/cholangiopancreatography (MRI\/MRCP) surveillance, and on-demand ERCP according to ESGE\/EASL guidelines \u2013 was collected. Patients with PSC diagnosed in 1990 or later were included and the last day of follow-up was 31 December 2023. The composite end point consisted of hepatobiliary malignancy, liver transplantation, or liver-related death.<\/jats:p>\n                  <jats:p>1629 PSC patients were included, with a median follow-up of 8\u201311 years. The cumulative incidence of the composite end point was lowest in the group undergoing scheduled ERCP (14.1%, 95%CI 12.0%\u201316.4%) and highest in the on-demand ERCP cohort (35.0%, 95%CI 28.4%\u201342.0%). Although the cumulative incidence of CCA was lower in the scheduled ERCP group than in the other groups, it did not differ statistically significantly from the MRI\/MRCP surveillance group. No differences were seen in liver-related deaths between the surveillance strategies.<\/jats:p>\n                  <jats:p>In this study comparing scheduled ERCP, annual MRI\/MRCP surveillance, and on-demand ERCP, the strategy based on scheduled ERCP using individual risk stratification is associated with better overall prognosis and outcome.<\/jats:p>","DOI":"10.1055\/a-2511-3422","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T19:46:49Z","timestamp":1738093609000},"page":"431-440","source":"Crossref","is-referenced-by-count":8,"title":["Surveillance of primary sclerosing cholangitis \u2013 a comparison of scheduled or on-demand ERCP with annual MRI surveillance: a multicenter study"],"prefix":"10.1055","volume":"57","clinical-trial-number":[{"clinical-trial-number":"nct03041662","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Nina","family":"Barner-Rasmussen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, HUS Abdominal Center, Helsinki University Central Hospital, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Molinaro","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Medicine, Wallenberg Laboratory, University of Gothenburg, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bregje","family":"Mol","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Amsterdam UMC Locatie AMC, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyriel","family":"Ponsioen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Amsterdam UMC Locatie AMC, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Bergquist","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannu","family":"Kautiainen","sequence":"additional","affiliation":[{"name":"Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland"},{"name":"Primary Health Care, Folkhalsan Research Centre, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martti A.","family":"F\u00e4rkkil\u00e4","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, HUS Abdominal Center, Helsinki University Central Hospital, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1053\/j.gastro.2021.07.046","article-title":"Defining primary sclerosing cholangitis: results from an International Primary Sclerosing Cholangitis Study group consensus process","volume":"161","author":"CY Ponsioen","year":"2021","journal-title":"Gastroenterology"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/s0168-8278(01)00288-4","article-title":"Hepatic and extrahepatic malignancies in primary sclerosing cholangitis","volume":"36","author":"A Bergquist","year":"2002","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3109\/00365521.2014.946085","article-title":"Colorectal cancer and cholangiocarcinoma in patients with primary sclerosing cholangitis and inflammatory bowel disease","volume":"50","author":"P Manninen","year":"2015","journal-title":"Scand J Gastroenterol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1002\/hep.26565","article-title":"Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis","volume":"58","author":"K Boonstra","year":"2013","journal-title":"Hepatology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1080\/00365521.2019.1707277","article-title":"Epidemiology, risk of malignancy and patient survival in primary sclerosing cholangitis: a population-based study in Finland","volume":"55","author":"N Barner-Rasmussen","year":"2020","journal-title":"Scand J Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3748\/wjg.v25.i6.659","article-title":"Cancer risk in primary sclerosing cholangitis: Epidemiology, prevention, and surveillance strategies","volume":"25","author":"BM Fung","year":"2019","journal-title":"World J Gastroenterol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.cgh.2014.02.008","article-title":"Low risk of hepatocellular carcinoma in patients with primary sclerosing cholangitis with cirrhosis","volume":"12","author":"R Zenouzi","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","article-title":"Primary sclerosing cholangitis - a comprehensive review","volume":"67","author":"TH Karlsen","year":"2017","journal-title":"J Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.jhep.2022.05.011","article-title":"Clinical Practice Guidelines on sclerosing cholangitis","volume":"77","author":"EASL","year":"2022","journal-title":"J Hepatol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jhep.2022.11.011","article-title":"Prospective surveillance for cholangiocarcinoma in unselected individuals with primary sclerosing cholangitis","volume":"78","author":"C Villard","year":"2023","journal-title":"J Hepatol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/liv.15286","article-title":"Impact on follow-up strategies in patients with primary sclerosing cholangitis","volume":"43","author":"A Bergquist","year":"2023","journal-title":"Liver Int"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1055\/s-0041-110792","article-title":"Screening primary sclerosing cholangitis and biliary dysplasia with endoscopic retrograde cholangiography and brush cytology: risk factors for biliary neoplasia","volume":"48","author":"S Boyd","year":"2016","journal-title":"Endoscopy"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0168-8278(01)00251-3","article-title":"Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment","volume":"36","author":"A Stiehl","year":"2002","journal-title":"J Hepatol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"e0415","DOI":"10.1097\/HC9.0000000000000415","article-title":"NGS of brush cytology samples improves the detection of high-grade dysplasia and cholangiocarcinoma in patients with primary sclerosing cholangitis: A retrospective and prospective study","volume":"8","author":"S Boyd","year":"2024","journal-title":"Hepatol Commun"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1080\/00365521.2023.2233038","article-title":"The role of serology, liver function tests and imaging in screening of primary sclerosing cholangitis: the HelPSCreen score","volume":"58","author":"N Barner-Rasmussen","year":"2023","journal-title":"Scand J Gastroenterol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/liv.15471","article-title":"Disease burden in primary sclerosing cholangitis in the Netherlands: A long-term follow-up study","volume":"43","author":"KN van Munster","year":"2023","journal-title":"Liver Int"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/hep.29730","article-title":"Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis","volume":"67","author":"AH Ali","year":"2018","journal-title":"Hepatology"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1053\/j.gastro.2020.05.049","article-title":"Effects of primary sclerosing cholangitis on risks of cancer and death in people with inflammatory bowel disease, based on sex, race, and age","volume":"159","author":"PJ Trivedi","year":"2020","journal-title":"Gastroenterology"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1053\/j.gastro.2017.02.038","article-title":"Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis","volume":"152","author":"T Weism\u00fcller","year":"2017","journal-title":"Gastroenterology"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/hep.32771","article-title":"AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma","volume":"77","author":"CL Bowlus","year":"2023","journal-title":"Hepatology"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1136\/gutjnl-2018-317993","article-title":"British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis","volume":"68","author":"MH Chapman","year":"2019","journal-title":"Gut"},{"key":"ref22","first-page":"e0442","article-title":"Surveillance MRI is associated with improved survival in patients with primary sclerosing cholangitis","volume":"8","author":"N Tan","year":"2024","journal-title":"Hepatol Commun"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1111\/liv.13899","article-title":"The role of magnetic resonance imaging and endoscopic retrograde cholangiography in the evaluation of disease activity and severity in primary sclerosing cholangitis","volume":"38","author":"A Tenca","year":"2018","journal-title":"Liver Int"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1136\/gutjnl-2018-316801","article-title":"Effect of scheduled endoscopic dilatation of dominant strictures on outcome in patients with primary sclerosing cholangitis","volume":"68","author":"C Rupp","year":"2019","journal-title":"Gut"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.dld.2021.05.009","article-title":"Use of thiopurines is not a risk factor for post- ERCP pancreatitis in patients with primary sclerosing cholangitis","volume":"53","author":"V Koskensalo","year":"2021","journal-title":"Dig Liver Dis"}],"container-title":["Endoscopy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2511-3422.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T18:32:52Z","timestamp":1745346772000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2511-3422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":25,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2025,4,22]]},"published-print":{"date-parts":[[2025,5]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2511-3422","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0013-726X","1438-8812"],"issn-type":[{"value":"0013-726X","type":"print"},{"value":"1438-8812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,28]]}}}